• ASND

Earnings call: Ascendis Pharma reports mixed Q2 2024 results, forecasts growth

Ascendis Pharma reported mixed Q2 results, highlighting successes in drug approvals and innovation efforts while facing revenue challenges, with strategic plans for future growth.